GPRC5D Videos

Videos

Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent

02/23/2023

Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.

Sundar Jagannath, MD, provides...

02/23/2023

Oncology

Dan Vogl, MD, University of Pennsylvania

Videos

Bispecific T-Cell Engagers and Novel Approaches for the Treatment of Multiple Myeloma

02/23/2023

Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.

Dan Vogl, MD discusses options...

02/23/2023

Oncology

Videos

What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?

02/16/2023

Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Faith E. Davies, MD, provides an...

02/16/2023

Oncology

Videos

Expedited FDA Approval of Teclistamab for Relapsed/Refractory Multiple Myeloma

02/05/2023

Ajai Chari, MD, provides insight into the FDA approval of teclistamab for relapsed/refractory multiple myeloma and background on the data that led to this approval.

Ajai Chari, MD, provides insight...

02/05/2023

Oncology

Videos

Daratumumab Plus Lenalidomide and Dexamethasone Demonstrates Survival Benefits for Transplant-Ineligible Patients With Newly Diagnosed MM

02/05/2023

Shaji K. Kumar, MD, discusses the PFS and OS benefit seen with daratumumab added to lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Shaji K. Kumar, MD, discusses...

02/05/2023

Oncology

Videos

Strategies for Treating Frail and Transplant-Ineligible Patients With Multiple Myeloma

01/26/2023

Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.

Shaji Kumar, MD, provides...

01/26/2023

Oncology

Videos

Talquetamab Demonstrates Robust Efficacy, Manageable Safety in Patients With Heavily Pretreated R/R Multiple Myeloma

12/12/2022

At the 2022 ASH Annual Meeting and Exposition in New Orleans, LA, Ajai Chari, MD, discusses talquetamab efficacy and safety for patients with heavily pretreated relapsed/refractory multiple myeloma.

At the 2022 ASH Annual Meeting...

12/12/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology